Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching.

Cancers (Basel) · 2026 · PMC12897004 · PMID 41681960

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The EOR-stratified findings in the present study were exploratory and did not reach statistical significance; therefore, they should not be interpreted as evidence of benefit or harm attributable to neoadjuvant bevacizumab. 4.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.